Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its ...

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

Novo Nordisk saw a significant decline as it lost over 55% from its highs in June 2024. Check out the reasons for the decline ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...